Is Teicoplaninum [INN-Latin] Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Teicoplaninum [INN-Latin]? Is Teicoplaninum [INN-Latin] safe for nursing mother and child? Does Teicoplaninum [INN-Latin] extracts into breast milk? Does Teicoplaninum [INN-Latin] has any long term or short term side effects on infants? Can Teicoplaninum [INN-Latin] influence milk supply or can Teicoplaninum [INN-Latin] decrease milk supply in lactating mothers?

Antibacterial glycopeptide, administered via intravenous or intramuscularinjection. Its pharmacokinetic data (high molecular weight, high percentage of plasma protein binding and no oral bioavailability) explain the negligible passage into milk observed (Fraissinet 2017) and the absence of side effects in a 52-day-old infant whose mother was being treated with Teicoplaninum [INN-Latin] (Kaplan 2017). Not being absorbed orally, there would be no passage to the infant's plasma from ingested breast milk. It is an antibiotic that is administered, if necessary, to newborns. The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to altered intestinal flora.

Teicoplaninum [INN-Latin] is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited data indicate that Teicoplaninum [INN-Latin] is poorly excreted into breastmilk. Because Teicoplaninum [INN-Latin] is not orally absorbed it is unlikely to adversely affect the breastfed infant. One infant was safely breastfed during maternal therapy with Teicoplaninum [INN-Latin] and ceftriaxone. Until more information becomes available, monitor the breastfed infant for gastrointestinal disturbances such as diarrhea, particularly in newborn and preterm infants.

A mother who was exclusively nursing her 52-day-old infant developed a soft-tissue infection. She was treated with intravenous Teicoplaninum [INN-Latin] 400 mg every 12 hours for 3 doses, then 400 mg daily for 5 days total, intravenous ceftriaxone 1 gram daily, and topical mupirocin cream twice daily. A careful follow-up indicated that her infant had no adverse effects.[2]